ESP-31015
ESP-31015 (ETC-1001) is an orally active and non-fibrate based PPARα agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 413624-55-2
- Formel: C17H34O3
- Molecular Weight:286.45
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
PPARα |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
1.5 μM
Compound: 39
|
Inhibition of lipid synthesis in primary rat hepatocytes by incorporation radiolabeled acetate into cellular lipids
Inhibition of lipid synthesis in primary rat hepatocytes by incorporation radiolabeled acetate into cellular lipids
|
[PMID: 16392818] |
| Hepatocyte | IC50 |
4 μM
Compound: 14c
|
Concentration required for inhibition of lipid synthesis in primary cultures of rat hepatocytes
Concentration required for inhibition of lipid synthesis in primary cultures of rat hepatocytes
|
[PMID: 15537362] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female obese Zucker fatty rats model[1]
-
Dosage:100 mg/kg
-
Administration:Oral administration (p.o.), once daily for 2 weeks
-
Result:Showed a 34.6% increase in serum HDL-cholesterol and a 71% reduction in serum triglycerides.
Chemical Information
-
CAS. Nr. 413624-55-2
-
Molecular Weight 286.45
-
Formel C17H34O3
-
SMILES
OCC(C)(C)CCCCC(CCCCC(C)(C)CO)=O
-
Synonyms
ETC-1001
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)